Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
However, biotech stocks offer a compelling risk-rewa.... |
Good MorningThe Federal Reserve’s quarter-point rate cut and signal of two more reductions this year sent Treasury yields lower and kept equities near record highs. The Dow rose 0.6%, while the S&P 500 and Nasdaq slipped slightly as investors weighed the dovish shift against growth concerns. Defensive stocks outperformed tech late in the session.
Tech and AI leaders remained in focus after upgrades highlighted strength in AI names, with NVIDIA leading momentum despite China export curbs. Meta is unveiling AI-powered glasses, and Amazon pledged $1 billion to boost wages and cut healthcare costs. Meanwhile, StubHub’s IPO fell 6% below its $23.50 debut price, underscoring mixed market sentiment. Featured: The 10-minute trade with zero dollars at risk (Ad) 
| Medical | |
Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
However, biotech stocks offer a compelling risk-rewa... Read the Full Story |
| From Our Partners | | AI doesn't run on chips - it runs on natural gas. Analysts are now tracking roughly 100 gigawatts of new behind-the-meter gas generation lining up behind the AI buildout, and on June 22, one of the world's largest energy companies signed a 20-year, 2.67-gigawatt deal to power a single data-center project.
Ken Griffin has reportedly put more than a billion dollars into this corner of the market. Porter Stansberry has identified two picks-and-shovels plays in AI's power supply, plus 6 stocks to buy and 10 to sell - all detailed in a new documentary. | | Watch the documentary now to see all 16 stock positions |
| Energy | |
A recent Buy upgrade from Melius Research has sharpened investor focus on GE Vernova (NYSE: GEV), accompanied by a new, optimistic $740 price target. This signal from Wall Street is underpinned by a powerful catalyst transforming the energy sector: the explosive growth of artificial intelligence... Read the Full Story |
| Finance | |
Macro is often an intimidating term for retail investors, as it encompasses everything from interest rates to inflation, employment, and global capital flows. However, macroeconomic forces are the true drivers behind every major market cycle.
Not Federal Reserve (the Fed) rate cuts or hikes, not ... Read the Full Story |
| From Our Partners | | Hedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger.
He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today. | | Watch Larry Benedict's presentation and get the one ticker now |
| Retail/Wholesale | |
Dave & Buster’s (NASDAQ: PLAY) FQ2 earnings report was no blowout with tepid revenue growth and a significant contraction in earnings.
However, it still highlights the company’s strengths and the significant potential for recovery, which has greatly improved. The company found i... Read the Full Story |
| Consumer Discretionary | |
Retail giant Nike Inc. (NYSE: NKE) and its stock have to be one of the industry's horror stories from recent years. After soaring through the pandemic, shares have since fallen in a near-continuous slide that's wiped out more than 60% of their value, while the major indices have been printing re... Read the Full Story |
| From Our Partners | | According to Yahoo Finance, Elon Musk's latest project could 'upend another industry just as he did with cars and rockets.' Tech investor Jeff Brown - a former senior executive at Qualcomm, Juniper Networks, and NXP Semiconductors - says one tiny chipmaker, 148 times smaller than NVIDIA, is set to supply Musk with 5 billion chips over the next two years.
Early investors in Tesla and SpaceX saw life-changing returns. Brown believes this overlooked chipmaker could offer a similar opportunity, with entry points currently around $50. | | Click here to see Jeff Brown's full breakdown of this chipmaker |
| Technology | |
Tech giant Oracle (NYSE: ORCL) recently put out an earnings report that left many market observers in awe. The company’s Q1 fiscal 2026 sales and adjusted earnings per share weren’t what impressed; Oracle actually missed estimates on both figures. However, Oracle’s outlook was ... Read the Full Story |
| Technology | |
Less than a week after providing a highly encouraging financial update that sent shares soaring, chip giant Broadcom (NASDAQ: AVGO) made another huge move.
On Sept. 10, shares surged by approximately 9.8%, eclipsing the 9.4% up-move seen after Broadcom’s Sept. 4 earnings report.
This all... Read the Full Story |
| Technology | |
The changes to MarketBeat’s screen for Most Upgraded Stocks posted since the FQ2 earnings reports were released are significant. These are perhaps the most critical changes in many quarters, as the AI market leaders are back in the analysts’ favor.
Stocks in the ranking include five o... Read the Full Story |
| Technology | |
A landmark $6.3 billion deal with AI chip leader NVIDIA (NASDAQ: NVDA) recently sent shares of CoreWeave (NASDAQ: CRWV) soaring, crystallizing the company’s crucial role in the artificial intelligence (AI) boom. The market’s excitement reflects a growing understanding of a classic in... Read the Full Story |
| Technology | |
CrowdStrike Holdings Inc. (NASDAQ: CRWD) is in a quiet period of sorts. The company won’t report earnings until the end of November, meaning investors have to get through what are notoriously sluggish months for stocks with no fuel beyond headline news to push CRWD stock higher.
Fortunate... Read the Full Story |
| Thursday's Early Bird Stock Of The Day argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. | Should I Buy argenex Stock? ARGX Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of argenex was last updated on Monday, July 13, 2026 at 6:38 PM.
argenex Bull Case -
The current stock price is around $799, indicating a strong market position and potential for growth.
-
Recent short interest has shown a slight decrease, suggesting that investor sentiment may be improving.
-
With an average daily volume of approximately 346,000 shares, there is significant trading activity, which can indicate liquidity and investor interest.
-
The company has maintained a consistent outstanding share count, which can help stabilize stock performance and reduce volatility.
-
Despite having no institutional ownership, this could mean that the stock is undervalued, presenting a potential opportunity for individual investors to capitalize on future growth.
argenex Bear Case -
The short percentage of float is around 3.56%, indicating that some investors are betting against the stock, which could lead to downward pressure.
-
There has been minimal month-to-month change in short interest, suggesting a lack of momentum in investor confidence.
-
With no institutional ownership, the stock may lack the backing of larger, more stable investors, which can be a red flag for potential volatility.
-
The company has not shown significant performance changes over the past year, which may indicate stagnation in growth or innovation.
-
Days to cover is approximately 6.22, which can suggest that if there is a sudden need to cover short positions, it could lead to increased volatility in the stock price.
| | View Today's Stock Pick |
|
| |
|
|
